In a major step for Indo-German cooperation in biotechnology, Novelix Pharmaceuticals Limited (formerly Trimurthi Limited) has announced a strategic partnership with GMBU e.V., a leading German non-profit research organization based in Halle (Saale). The collaboration will enable the technology transfer and large-scale production of Astaxanthin, a powerful natural antioxidant, at Novelix’s upcoming facility in Hyderabad.
German Technology Meets Indian Manufacturing Strength
Under the agreement, GMBU e.V. will transfer its proprietary cultivation technology and bioprocess expertise to Novelix, supporting the company’s transition from pilot research to full-scale production.
Novelix plans to invest significantly in infrastructure and a GMP-certified manufacturing facility at its Techno Park site, positioning itself to serve markets across Europe, North America, and India.
Founded in 1992, GMBU e.V. is known for bridging academic and industrial innovation, with specializations in biotechnology, chemical and bioprocess engineering, bioanalytics, and nanotechnology. The partnership reflects Germany’s strong scientific tradition aligning with India’s expanding industrial capabilities.
Milestone for Indo–German Collaboration
The collaboration is being hailed as a milestone in Indo-German biotech cooperation, emphasizing mutual strengths in research, innovation, and sustainable production.
By leveraging GMBU’s know-how and Novelix’s production capacity, the initiative aims to make bioactive compounds like Astaxanthin more accessible and affordable globally.
Dr. Enrico Ehrhardt, Head of Molecular Biology at GMBU e.V., described the collaboration as a landmark development for scaling up biotechnological innovation. He noted that the partnership opens new opportunities for joint research, product development, and sustainable healthcare solutions.
Scaling Innovation for Global Markets
Astaxanthin—sourced from microalgae—is valued for its antioxidant and anti-inflammatory properties, widely used in nutraceuticals, skincare, and pharmaceuticals.
With global demand for natural antioxidants growing rapidly, the partnership gives Novelix a competitive edge through GMBU’s advanced bioprocess technology.
Mr. Gattu Gyan Prakash, Director of Novelix Pharmaceuticals Limited, said the agreement reflects a new model of Indo-German collaboration, blending research excellence with strategic infrastructure.
“This partnership goes beyond product development,” he said. “It represents the convergence of science, technology, and manufacturing strength—placing both organizations at the forefront of innovation in biotechnology and nutraceuticals.”
As Germany contributes cutting-edge R&D expertise and India provides large-scale production capability and market access, the collaboration embodies a mutually beneficial model of technology partnership.
